From policy to practice: Experiences from the ECHO trial following revisions of the WHO medical eligibility criteria for contraceptive use (MEC) guidance on DMPA-IM

• Príomhchruthaitheoirí: Petrus Steyn (Údar), Mags Beksinska (Údar), Melanie Pleaner (Údar), Hui-Zhen Tam (Údar), Jenni Smit (Údar), Kathy Baisley (Údar), Douglas Taylor (Údar), Mandisa Singata-Madliki (Údar), G. Justus Hofmeyr (Údar), Thesla Palanee-Phillips (Údar), James N. Kiarie (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Elsevier, 2024-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Objectives: In 2017, the World Health Organization (WHO) medical eligibility criteria (MEC) for contraception category for intramuscular depot medroxyprogesterone acetate (DMPA-IM) was changed from MEC category 1 to 2 for women at high risk of HIV acquisition. We assessed the impact of communicating...